

AMENDMENTS TO THE CLAIMS

The claims as listed below will replace all prior listings and presentations of claims in the above-identified application. The specific changes to any amended claims are shown by strikethrough or double bracketing for any deletions, and underlining for any insertions.

Please amend Claims 48, 67 and 70, cancel Claims 1-6, 46, 47, 52-57 and 69, and add new Claim 73 as follows:

1.-47. **(Canceled).**

48. **(Currently amended)** A method of treating an ocular disorder, comprising:

introducing an implant comprising a therapeutic drug into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;
and

advancing the distal end of said implant into eye tissue adjacent the anterior chamber such that the implant drains aqueous humor from the anterior chamber into a physiologic ~~physiological~~ outflow pathway and the therapeutic drug reaches eye tissue.

49. **(Previously Presented)** The method of Claim 48, wherein the implant is coated with said therapeutic drug.

50. **(Previously Presented)** The method of Claim 48, wherein advancing the implant into eye tissue involves positioning at least a portion of the implant so as to contact a choroid of the eye.

51. **(Previously Presented)** The method of Claim 48, wherein advancing the implant into eye tissue involves positioning a distal end of the implant so as to drain aqueous humor toward a choroid of the eye.

52.-57. **(Canceled).**

58. **(Previously Presented)** A method of treating an ocular disorder, comprising:

introducing an implant comprising a therapeutic drug into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;
and

advancing the distal end of said implant into eye tissue such that the implant is in contact with at least a choroid of the eye.

59. **(Previously Presented)** The method of Claim 58 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

60. **(Previously Presented)** The method of Claim 58 additionally comprising controlling aqueous humor flow through a lumen of the implant.

61. **(Previously Presented)** The method of Claim 58, wherein the implant includes a hollow filled with the therapeutic drug.

62. **(Previously Presented)** The method of Claim 58, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

63. **(Previously Presented)** The method of Claim 58, wherein the therapeutic drug comprises a compound of drugs, at least one of which is therapeutic.

64. **(Previously Presented)** A method of treating an ocular disorder, comprising:

forming an incision in an eye;

inserting an implant through the incision into an anterior chamber of the eye such that at least a distal end of the implant is temporarily in the anterior chamber, the implant comprising a therapeutic drug; and

inserting the distal end of the implant into eye tissue such that the implant drains aqueous humor from the anterior chamber toward a choroid of the eye.

65. **(Previously Presented)** The method of Claim 64 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

66. **(Previously Presented)** The method of Claim 64, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

67. **(Currently Amended)** A method of treating an ocular disorder, comprising:

introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

placing [[an]] the implant in contact with a choroid of [[an]] the eye by advancing the distal end of the implant into eye tissue, said implant having at least one flow channel;

flowing a fluid, which comprises aqueous humor, along the flow channel of the implant; and

eluting a therapeutic agent from the implant.

68. **(Previously Presented)** The method of Claim 67 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.

69. **(Canceled).**

70. **(Currently Amended)** A method of treating an ocular disorder, comprising:
providing an implant having at least one lumen extending between an inlet and an outlet, and at least one anchor projecting outwardly from the lumen;

introducing the implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

using the anchor to retain the implant in eye tissue;

positioning the outlet in tissue so as to fluidically communicate directly with a physiologic outflow pathway; and

eluting a therapeutic agent from the implant.

71. **(Previously Presented)** The method of Claim 70 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.

72. **(Previously Presented)** The method of Claim 70 wherein the method further comprises advancing the implant through scleral tissue of the eye when positioning the outlet.

73. **(New)** A method of treating an ocular disorder, comprising:

providing an implant having at least one anchor;

introducing the implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;

inserting at least a portion of the implant into eye tissue at an implantation site without penetrating through a cornea or a sclera of the eye;

using the anchor to retain the implant at said implantation site; and

eluting a therapeutic agent from the implant.